SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)
NCT06401005
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
51
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Cadonilimab (AK104)
Sponsor
Hubei Cancer Hospital